Medicine & Life Sciences

1. Lymphoma 100%
2. Lymphoma, Large B-Cell, Diffuse 90%
3. Non-Hodgkin's Lymphoma 54%
4. Follicular Lymphoma 43%
5. Waldenstrom Macroglobulinemia 38%
6. Survival 38%
7. Hodgkin Disease 31%
8. Progression-Free Survival 29%
9. Survivors 25%
10. Rituximab 23%
11. Molecular Epidemiology 19%
12. Confidence Intervals 19%
13. Hematology 17%
14. Quality of Life 17%
15. Neoplasms 16%
16. Anthracyclines 16%
17. B-Cell Lymphoma 16%
18. Methotrexate 16%
19. Drug Therapy 15%
20. Recurrence 14%
21. Therapeutics 14%
22. B-Lymphocytes 13%
23. Genome-Wide Association Study 13%
24. Survivorship 13%
25. Monocytes 12%
26. Incidence 12%
27. Pneumocystis Pneumonia 11%
28. Clinical Trials 10%
29. Lymphocyte Count 10%
30. B-Cell Chronic Lymphocytic Leukemia 10%
31. Cohort Studies 10%
32. Odds Ratio 9%
33. Cyclophosphamide 9%
34. Lymphocytes 8%
35. Mantle-Cell Lymphoma 8%
36. Genetic Predisposition to Disease 8%
37. Population 8%
38. Acute Kidney Injury 8%
39. Complementary Therapies 8%
40. Genetic Profile 8%
41. Patient Reported Outcome Measures 8%
42. Guidelines 7%
43. Doxorubicin 7%
44. Exercise 7%
45. Transplants 7%
46. T-Cell Lymphoma 7%
47. Biomarkers 7%
48. Light 7%
49. Essential Thrombocythemia 6%
50. Hematologic Neoplasms 6%